Magic mushrooms and truffles: same conversation, different products

Walk into a Dutch smartshop and you'll find fresh magic truffles in the fridge. Ask for magic mushrooms and the answer is a polite no. Both contain the same psychoactive compound, so why the different treatment? Let's sort out what these products are, where the line falls, and what the research does (and doesn't) say.

First, the fridge test

Here's the map before we go into the detail:

• Magic truffles are sclerotia: dense, underground storage structures of certain psilocybin-producing fungi. Magic mushrooms (paddo's in Dutch) are the fruiting bodies of those fungi. Both contain psilocybin, which the body converts to psilocin.
• In the Netherlands, as of 8 October 2026, selling mushrooms has been prohibited since 1 December 2008, and fresh truffles are sold legally in smartshops. Dried truffles are the grey area, because sources disagree (details below). The statute text names mushrooms, psilocine and psilocybine, but not truffles.
• Dutch rules are not European rules. Outside the Netherlands, check each country; Czechia, for example, has a medical route in law from 1 January 2026, though its health institute said in March that treatment wasn't available yet.
• Clinical trials are not shop use. The positive depression trials gave participants a defined, often synthetic, psilocybin dose in a clinic, with preparation, monitoring and therapeutic support.
• Risks are real and specific: anxiety and panic, raised heart rate and blood pressure, and serious cautions for people with psychotic conditions or on certain medicines such as lithium.

Law changes, so treat every legal point here as a dated snapshot and check current rules before you act on it.

What psilocybin actually is

Psilocybin is a naturally occurring compound made by several fungal genera, most famously Psilocybe. It is a prodrug: after you swallow it, the body rapidly converts it to psilocin, the pharmacologically active form (Otto et al., 2025, Clinical Pharmacokinetics, a systematic review of psilocin pharmacokinetics). Dutch addiction-care organisation Jellinek lists psilocine and psilocybine together as the active substances in both mushrooms and truffles (Jellinek).

That shared chemistry is why the two products get lumped together. It is also why they are easy to misjudge: the same compound can arrive in very different packages.

Truffle or mushroom: same organism, different organ

Think of the fungus as a plant with different organs. The mushroom is the above-ground fruiting body that releases spores. The "truffle" is a sclerotium, a hardened mass of fungal tissue that some species form underground as a reserve. Not every psilocybin-producing species forms them.

(A small naming trap: "magic truffles" are unrelated to the culinary truffles chefs shave over pasta. All they share is the underground habit and the name.)

• : What it is; Magic truffles (sclerotia): Underground storage structure; Magic mushrooms (paddo's): Fruiting body (cap and stem)
• : Active compounds; Magic truffles (sclerotia): Psilocybin (and psilocin); Magic mushrooms (paddo's): Psilocybin and psilocin
• : Dutch status, 8 Oct 2026; Magic truffles (sclerotia): Fresh: sold in smartshops, treated under the Commodities Act (Warenwet). Dried: sources disagree (see below); Magic mushrooms (paddo's): Sale banned since 1 Dec 2008 (Opium Act List II, fresh or dried)
• : Typical shop form; Magic truffles (sclerotia): Sold fresh in Dutch smartshops; Magic mushrooms (paddo's): Not sold in Dutch shops
• : Reliability of content; Magic truffles (sclerotia): Varies by batch and species; Magic mushrooms (paddo's): Varies by species, flush and drying

Is one "stronger"? You can't answer that from the name alone. In one laboratory analysis of Psilocybe sclerotia, psilocybin content ranged from 59.3 to 167.8 µg per 100 mg of fresh sclerotia, with no psilocin detected in those samples (Pellegrini et al., 2013, Drug Testing and Analysis). That's a nearly threefold spread across the sclerotia tested. Water content, species, batch and storage all move the number, so weight on a label is not a standard measure of "how much", and comparing fresh truffle weight with dried mushroom weight is not like-for-like.

Why the Netherlands treats them differently

Drug laws are drafted precisely, and that precision is what splits these two products. Here's what the sources say, read on 8 October 2026.

• The statute. On the Opium Act text (Opiumwet, on wetten.overheid.nl), psilocine and psilocybine are on List I. "Paddo's A", mushrooms that naturally contain psilocine or psilocybine, are on List II. The text names no truffles or sclerotia. Article 3 prohibits cultivating and possessing List II substances (the page shows amendments without an in-force date that were not opened).
• Mushrooms. On 1 December 2008 hallucinogenic mushrooms were placed on List II, ending sales of paddo's. DRUGSinfo (the national drug-information site) states: "Het is sinds 2008 verboden in Nederland om paddo's te verkopen."
• Truffles. Sclerotia are botanically not mushrooms. In answers to parliamentary questions in December 2011, the Dutch government said psychedelic truffles "vallen niet onder de Opiumwet" and fall under the Commodities Act instead (Kamerstukken, Aanhangsel 2011–2012, no. 1032). Jellinek, DRUGSinfo and Drugs en Uitgaan all describe fresh truffles as sold legally in smartshops.
• Dried truffles: the sources split. Jellinek (page version January 2021) says dried truffles fall under List I (Jellinek). DRUGSinfo and Drugs en Uitgaan simply say truffles aren't covered by the Opium Act and don't mention drying. The sources don't settle it, so dried truffles are best treated as unresolved; if you're weighing a dried product, treat it as the riskier reading.

So the line is not "psilocybin yes or no" but "which product, in what form". A fresh sclerotium sits on one side, and the same sclerotium dried may sit on the other.

Did anything change in 2025 or 2026?

A Dutch ban on certain designer-drug groups took effect on 1 July 2025 (government information from Rijksoverheid). The government page doesn't mention truffles, and nothing else we found changes the position above.

Some commercial and legal-guide pages mention a "January 2026 decree" with a €150 fine, and others say truffles were "regulated and taxed" from 2019. No official Dutch source supports either, and DRUGSinfo and Jellinek say otherwise. If you spot an official Dutch government source for a change, tell us and we'll update this page.

On the medical side, a 2025 overview in the Tijdschrift voor Psychiatrie discusses psychedelics in psychiatric treatment today (Tijdschrift voor Psychiatrie, 2025). It's a place to read more about the medical side.

Beyond the Netherlands

Don't carry Dutch assumptions across a border. Outside the Netherlands, check each country: many control psilocybin in every form, though we haven't surveyed them. Some orientation points, all dated to October 2026:

• Czechia. Parliament approved changes in 2025 that, effective 1 January 2026, allow therapeutic psilocybin to be administered in specialised healthcare facilities. The country's National Institute of Mental Health said on 23 March 2026 that treatment was not yet available, that patients could not yet apply or join a waiting list, and that launch was expected in the second half of 2026 (NUDZ statement). Whether treatment has since started isn't confirmed in the sources. This is a medical route, not recreational legality.
• Germany. Press reporting in August 2025 described the regulator approving a small, strictly controlled psilocybin access programme for treatment-resistant depression (Forbes). That's a news report rather than the regulator's own notice, so treat it as secondary.
• Anywhere else, check the exact form (fresh sclerotia, dried material, mushrooms, capsules) against an official source for that country before assuming anything.

What the clinical trials tested

Psilocybin research has moved quickly, and it's easy to blur the line between a clinic trial and a shop product. Here's what the trials did.

The studied product was a defined dose with support. In a phase 2 trial of treatment-resistant depression, 233 adults received a single dose of a proprietary synthetic psilocybin (25 mg, 10 mg or 1 mg as a control) with psychological support. The 25 mg group improved more than the 1 mg group at week 3 (a difference of 6.6 points on a 60-point depression scale), but adverse effects were more common (Goodwin et al., 2022, NEJM).

In a US phase 2 trial of major depressive disorder, 104 adults were randomised to a single 25 mg dose of synthetic psilocybin or 100 mg of niacin as the comparison, both with psychological support. By day 43, depression scores had fallen by 12.3 more points on the 60-point MADRS scale in the psilocybin group (95% CI −17.5 to −7.2), with no serious adverse events reported. The trial excluded people with a history of psychosis or mania (Raison et al., 2023, JAMA).

A 59-person trial comparing two 25 mg doses of psilocybin with six weeks of the antidepressant escitalopram found no statistically significant difference on its primary measure; some secondary measures favoured psilocybin (Carhart-Harris et al., 2021, NEJM).

Phase 3 results are arriving. Press-reported topline results from Compass Pathways' COMP006 trial (announced 17 February 2026) described two 25 mg doses, three weeks apart, beating a 1 mg control on the primary depression measure at week 6. Common adverse events included headache, nausea, anxiety and visual hallucination, and serious adverse events occurred in 2% of participants (HCPLive report). That is company topline data, not yet a peer-reviewed paper.

What this means for truffles. Those trials used synthetic or purified psilocybin in measured doses, with screening, preparation sessions, trained support and follow-up. Truffles vary in content (see above) and the retail setting has none of that structure. Trial results show what a specific intervention did in specific participants; they don't transfer automatically to a shop product used without screening or support. NCCIH, the US government's research centre for complementary health, makes the same distinction and says experiences can be unpredictable (NCCIH).

Microdosing (small, repeated amounts) is a separate question, with a thinner controlled evidence base than the supervised full-dose trials above and mostly small or null results against placebo.

The risks, in plain terms

This is the part of the picture that rarely fits on a product label.

• Psychological reactions. NCCIH lists anxiety, paranoia, confusion, panic and hallucinations among reported adverse effects, and says some people have unpleasant experiences involving extreme fear.
• Heart rate and blood pressure. The same NCCIH page lists increased blood pressure and heart rate among adverse effects. Anyone with heart or blood-pressure problems has an extra reason to talk to a doctor first.
• Psychotic conditions. NCCIH says psilocybin is not safe for people with conditions such as schizophrenia or schizoaffective disorder, or severe forms of bipolar disorder. The Raison trial excluded people with a history of psychosis or mania.
• Medicines. Interaction evidence is thin, which is not the same as reassurance. A study of online experience reports found that 47% of 62 reports of classic psychedelics taken with lithium involved seizures, compared with none of 34 reports with lamotrigine; the authors called the finding provisional (Nayak et al., 2021, Pharmacopsychiatry). NCCIH says it is funding research on interactions with psychiatric medicines such as SSRIs, so the answer isn't established yet. In the Raison trial, people on psychiatric medicines were eligible only after tapering, so a medicine-free state was part of the studied protocol. If you take any prescription medicine, our supplement and drug interactions guide explains how to check, and your pharmacist or doctor is the person to ask. Don't stop prescribed medication to try a product.
• Driving and work. Impairment is the practical risk everyone overlooks. Jellinek says driving after use is prohibited.

If someone is in severe distress, can't be roused, has chest pain, or is having a seizure, call 112 (the EU emergency number) and tell the responders what was taken.

What to compare when you're looking at products

This page doesn't assess any specific product, so here is a checklist instead of a recommendation:

1. Which form is it? Fresh sclerotia, dried material and mushroom-derived products sit under different Dutch rules, and the dried form is the disputed one.
2. What does the pack say, and who says it? Strength categories and "effects" descriptions are supplier statements. They're not a standard unit, and the 59–168 µg per 100 mg spread above shows why.
3. Where will it be used and carried? A Dutch smartshop listing is not legal clearance for every use, such as carrying a product abroad.
4. What does the shop say about shelf life and storage? That's supplier information, not independent testing, and it matters most for fresh material.

The truffle, the mushroom and where to read next

If you came here wondering whether the truffle in the fridge and the mushroom in the news are "the same thing", the answer is chemically yes, legally no, and clinically neither is the thing in the trials. For reading any pack with a cool head, the supplement label guide walks through reading a label step by step.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.